Sutro Biopharma Inc STRO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:20 PM EDT
3.40UNCH (UNCH)
Volume
28,554
Close
3.40quote price arrow down-0.12 (-3.55%)
Volume
495,390
52 week range
2.01 - 6.13
Loading...
  • Open3.50
  • Day High3.51
  • Day Low3.35
  • Prev Close3.52
  • 52 Week High6.13
  • 52 Week High Date03/28/24
  • 52 Week Low2.01
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap277.591M
  • Shares Out81.76M
  • 10 Day Average Volume0.63M
  • Dividend-
  • Dividend Yield-
  • Beta1.06
  • YTD % Change-20.86

KEY STATS

  • Open3.50
  • Day High3.51
  • Day Low3.35
  • Prev Close3.52
  • 52 Week High6.13
  • 52 Week High Date03/28/24
  • 52 Week Low2.01
  • 52 Week Low Date11/13/23
  • Market Cap277.591M
  • Shares Out81.76M
  • 10 Day Average Volume0.63M
  • Dividend-
  • Dividend Yield-
  • Beta1.06
  • YTD % Change-20.86

RATIOS/PROFITABILITY

  • EPS (TTM)-1.79
  • P/E (TTM)-1.89
  • Fwd P/E (NTM)-0.98
  • EBITDA (TTM)-82.462M
  • ROE (TTM)-58.25%
  • Revenue (TTM)153.731M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-69.47%
  • Debt To Equity (MRQ)2.71%

EVENTS

  • Earnings Date05/13/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sutro Biopharma Inc

 

Profile

MORE
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers...
Connie Matsui
Independent Chairman of the Board
William Newell J.D.
Chief Executive Officer, Director
Jane Chung
President, Chief Operating Officer
Edward Albini
Chief Financial Officer
Address
111 Oyster Point Blvd.
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
XERS
Xeris Biopharma Holdings Inc
1.75UNCHUNCH
AGEN
Agenus Inc
12.12-0.64-5.02%
KPTI
Karyopharm Therapeutics Inc
1.03-0.07-6.36%
AKBA
Akebia Therapeutics Inc
1.26-0.06-4.55%
FGEN
FibroGen Inc
1.12+0.03+2.75%